Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Development and Clinical Validation of Artificial Intelligence Algorithms for Sleep Staging and Obstructive…
In recent years, wearable and contactless devices, including smart rings, smart bands/watches, and smart mattresses, have developed rapidly and can continuously collect multidimensional data such as heart rate, oxygen saturation, respiration, body movement, snoring, body temperature, and environmental parameters. Nevertheless, most current consumer-grade or wellness-oriented devices have not been trained and validated using large polysomnography (PSG)-synchronized reference datasets.
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 1,000 people at Beijing. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Development and Clinical Validation of Artificial Intelligence Algorithms for Sleep Staging and Obstructive Sleep Apnea Screening Based on a Large-Scale Model Trained on Multimodal Physiological Signals From Diverse Populations
Primary outcome (registry wording): The sensitivity and specificity of the OSA-screening model
Who it is for (from inclusion criteria)
Ages 18 Years to 65 Years
Study Population 1: Individuals scheduled to undergo standard full-night PSG at a participating center
Participants must meet all of the following criteria:
Aged 18-65 years, of either sex
Able to complete standard full-night attended Type I PSG
Able to wear a smart ring and a continuous body-temperature patch and to use a contactless sleep-monitoring belt concurrently during PSG
Able to complete study-related questionnaires and collection of basic information
Study Population 2: Recruited healthy volunteers or volunteers at low risk for sleep disorders. Participants must meet all of the following criteria:
Who the registry excludes
A participant meeting any of the following criteria will be excluded:
Unable to complete full-night PSG
Unable to wear or use the study devices, or has clear intolerance to the devices or adhesive materials
Requires continuous positive airway pressure (CPAP), noninvasive ventilation, supplemental oxygen, or another medical device during the night that may significantly interfere with signal acquisition from PSG or the study devices
Has persistent atrial fibrillation, a severe or unstable medical condition, significant organ dysfunction, or any condition that substantially affects sleep
Has severe cognitive impairment, psychiatric or behavioral abnormalities, or another condition that prevents understanding of the study or cooperation with study procedures
Is considered by the investigator to be unsuitable for completion of overnight monitoring
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.
This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07908160?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07908160?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.